Clinical Trials in Austin

Showing 3641-3660 of 15,205 trials

A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream

NCT06213831

This study is being conducted to determine the safety and tolerability of ruxolitinib 1.5% cream under maximal use conditions in participants with Prurigo Nodularis (PN).

Prurigo Nodularis

Incyte Corporation23 participantsStarted Feb 2024

Phoenix, Arizona, United States • Scottsdale, Arizona, United States • Fountain Valley, California, United States +17 more locations

Active Not RecruitingPhase 2/3< 1 mile

A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME

NCT06571045

EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME) In the first year, all 3 treatment groups will be treated every 4 weeks with either EYE103 or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm. Approximately 960 participants will be entered in the study.

Diabetic Macular Edema (DME)

EyeBiotech Ltd.984 participantsStarted Aug 2024

Scottsdale, Arizona, United States • Fayetteville, Arkansas, United States • Springdale, Arkansas, United States +180 more locations

A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream

A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME

Find Trials by Condition in Austin

Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis

A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa

A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic

Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

Nonalcoholic Fatty Liver Disease (NAFLD) Database 3

COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations

The MOOD Study - External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for the Treatment of Major Depressive Disorder (MDD)

Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)

A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis

Expanded Access of Sotorasib

A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors

Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours